Imipramine enhances neuroprotective effect of PEP-1-Catalase against ischemic neuronal damage

• Published in: BMB reports Vol. 44; no. 10; pp. 647 - 652
• Main Authors: Kim, Dae-Won, Kim, Duk-Soo, Kim, Mi-Jin, Kwon, Soon-Won, Ahn, Eun-Hee, Jeong, Hoon-Jae, Sohn, Eun-Jeong, Dutta, Suman, Lim, Soon-Sung, Cho, Sung-Woo, Lee, Kil-Soo, Park, Jin-Seu, Eum, Won-Sik, Hwang, Hyun-Sook, Choi, Soo-Young
• Format: Journal Article
• Language: Korean
• Published: 생화학분자생물학회 30.10.2011
• Subjects: Imipramine; Ischemic damage; PEP-1-CAT; Protein transduction; PEP-1-CAT; Imipramine; Ischemic damage; Protein transduction
• ISSN: 1976-6696; 1976-670X

The protein transduction domains have been reported to have potential to deliver the exogenous molecules, including proteins, to living cells. However, poor transduction of proteins limits therapeutic application. In this study, we examined whether imipramine could stimulate the transduction efficiency of PEP-1 fused proteins into astrocytes. PEP-1-catalase (PEP-1- CAT) was transduced into astrocytes in a time- and dose-dependent manner, reducing cellular toxicity induced by H2O2. Additionally, the group of PEP-1-CAT + imipramine showed enhancement of transduction efficiency and therefore increased cellular viability than that of PEP-1-CAT alone. In the gerbil ischemia models, PEP-1-CAT displayed significant neuroprotection in the CA1 region of the hippocampus. Interestingly, PEP-1-CAT + imipramine prevented neuronal cell death and lipid peroxidation more markedly than PEP-1-CAT alone. Therefore, our results suggest that imipramine can be used as a drug to enhance the transduction of PEP-1 fusion proteins to cells or animals and their efficacies against various disorders. [BMB reports 2011; 44(10): 647-652]